Nothing Special   »   [go: up one dir, main page]

MX2016009352A - Inhibidores de quinasa a base de quinolina. - Google Patents

Inhibidores de quinasa a base de quinolina.

Info

Publication number
MX2016009352A
MX2016009352A MX2016009352A MX2016009352A MX2016009352A MX 2016009352 A MX2016009352 A MX 2016009352A MX 2016009352 A MX2016009352 A MX 2016009352A MX 2016009352 A MX2016009352 A MX 2016009352A MX 2016009352 A MX2016009352 A MX 2016009352A
Authority
MX
Mexico
Prior art keywords
quinoline
kinase inhibitors
based kinase
aaki
compounds
Prior art date
Application number
MX2016009352A
Other languages
English (en)
Inventor
E Macor John
J Bronson Joanne
Diane Dzierba Carolyn
Jethanand Nara Susheel
Sivasamban Karatholuvhu Maheswaran
A Hartz Richard
T Ahuja Vijay
Dasgupta Bireshwar
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2016009352A publication Critical patent/MX2016009352A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención está dirigida en general a los compuestos de la fórmula (I) que pueden inhibir a la AAK1 (quinasa 1 asociada al receptor), a las composiciones que comprenden tales compuestos, y a los métodos de inhibición de la AAK1.
MX2016009352A 2014-01-31 2015-01-23 Inhibidores de quinasa a base de quinolina. MX2016009352A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461934152P 2014-01-31 2014-01-31
PCT/US2015/012649 WO2015116492A1 (en) 2014-01-31 2015-01-23 Quinoline-based kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2016009352A true MX2016009352A (es) 2016-10-13

Family

ID=52474081

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009352A MX2016009352A (es) 2014-01-31 2015-01-23 Inhibidores de quinasa a base de quinolina.

Country Status (9)

Country Link
US (1) US9932320B2 (es)
EP (1) EP3099673B1 (es)
JP (1) JP6441947B2 (es)
CN (1) CN106132951B (es)
CA (1) CA2937501A1 (es)
EA (1) EA201691397A1 (es)
ES (1) ES2701903T3 (es)
MX (1) MX2016009352A (es)
WO (1) WO2015116492A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10253027B2 (en) 2013-07-08 2019-04-09 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
EP3054955B1 (en) 2013-10-11 2018-05-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
HUE041457T2 (hu) 2014-04-02 2019-05-28 Bristol Myers Squibb Co Biaril kináz inhibitorok
WO2016164295A2 (en) * 2015-04-10 2016-10-13 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
CN108290843B (zh) 2015-10-01 2021-08-24 百时美施贵宝公司 联芳基激酶抑制剂
KR102704295B1 (ko) 2015-10-01 2024-09-05 브리스톨-마이어스 스큅 컴퍼니 비아릴 키나제 억제제
SG11201802952TA (en) * 2015-10-09 2018-05-30 Agency Science Tech & Res Compounds for treatment of cancer and epigenetics
EP3260445A1 (en) * 2016-06-24 2017-12-27 Universität Konstanz Compounds for use as an anti-bacterial or anti-fungal agent and as a zinc sensor
CN107501180B (zh) * 2017-09-13 2020-06-05 新乡医学院 一种喹啉-4-甲酰胺类化合物的合成方法
EP3502095A1 (en) 2017-12-22 2019-06-26 Universität Konstanz Compound for use against pathogenic neisseria and haemophilus species and moraxella catarrhalis
CN109734705B (zh) * 2019-02-01 2021-09-28 浙江工业大学 一种经脱卤烷基化制备n-杂环芳烃衍生物的方法
WO2021050913A1 (en) * 2019-09-12 2021-03-18 Disarm Therapeutics, Inc. Inhibitors of sarm1
CN113387965A (zh) * 2021-06-17 2021-09-14 南京邮电大学 一种有机电子受体材料及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407370A1 (en) 2000-04-24 2001-11-01 Bristol-Myers Squibb Company Heterocycles that are inhibitors of impdh enzyme
RU2014140739A (ru) * 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения
JP6418950B2 (ja) * 2012-03-09 2018-11-07 レクシコン ファーマシューティカルズ インコーポレイテッド ピラゾロ［１，５−ａ］ピリミジン系化合物、それを含む組成物、及びそれらを使用する方法
JP2015513557A (ja) * 2012-03-09 2015-05-14 レクシコン ファーマシューティカルズ インコーポレイテッド 疼痛の治療に対するアダプター関連キナーゼ１の阻害
US8703953B2 (en) * 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
WO2016053794A1 (en) 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors

Also Published As

Publication number Publication date
EA201691397A1 (ru) 2016-11-30
WO2015116492A1 (en) 2015-08-06
CN106132951B (zh) 2019-02-12
US9932320B2 (en) 2018-04-03
JP6441947B2 (ja) 2018-12-19
JP2017504652A (ja) 2017-02-09
ES2701903T3 (es) 2019-02-26
CA2937501A1 (en) 2015-08-06
CN106132951A (zh) 2016-11-16
EP3099673A1 (en) 2016-12-07
EP3099673B1 (en) 2018-09-26
US20160332985A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
MX2016009352A (es) Inhibidores de quinasa a base de quinolina.
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
MX2016012829A (es) Inhibidores de biaril cinasa.
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
PH12017501925A1 (en) Pyrazole compounds and method for making and using the compounds
PH12017502050A1 (en) Naphthyridine compounds as jak kinase inhibitors
MX2017003930A (es) Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
SG10201809518QA (en) Processes of preparing a jak1 inhibitor and new forms thereto
MY194262A (en) Inhibitors of ret
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
PH12019550235A1 (en) Kinase inhibitors and uses thereof
MX383935B (es) Amidas heterocíclicas como inhibidores de cinasa.
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
MX2016002924A (es) Inhibidores de cinasa a base de eter arilico.
MX2015000980A (es) Inhibidores de aril lactama cinasa.
MX2016009355A (es) Inhibidores de aril lactama cinasa.
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
NZ742952A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
MA39824A (fr) Composés azole amido-substitués